opioid growth factor + gemcitabine

opioid growth factor + gemcitabine is an investigational antineoplastic combination regimen studied primarily for advanced unresectable pancreatic adenocarcinoma. The regimen pairs opioid growth factor, an endogenous peptide also known as [Met5]-enkephalin that signals through the opioid growth factor receptor to tonically suppress cell proliferation by delaying the G1/S transition, with gemcitabine, a deoxycytidine analog chemotherapy that inhibits DNA synthesis after intracellular activation and incorporation into DNA. Available preclinical and clinical literature describes this as a dual-agent biotherapy plus chemotherapy approach rather than a single branded drug product, with academic development including clinical evaluation at Milton S. Hershey Medical Center.

Other names

opioid growth factor + gemcitabineOGF + gemcitabine[Met5]-enkephalin + gemcitabinemethionine enkephalin + gemcitabine